Wegovy and Metformin Interaction: What Patients and Clinicians Need to Know

What do the labels say about Wegovy plus metformin?

Wegovy injection is semaglutide 2.4 mg once weekly for weight management; the recommended maintenance dose is 2.4 mg, and adults who tolerate 2.4 mg for at least 4 weeks and need more weight loss may go to a maximum of 7.2 mg weekly [1]. Metformin is an oral biguanide labeled as an adjunct to diet and exercise for type 2 diabetes in adults and children 10 and older; weight loss, prediabetes and PCOS are not labeled uses [2]. The Wegovy drug interactions section addresses insulin and insulin secretagogues and oral medicines affected by delayed gastric emptying; it does not name metformin [1]. The metformin label's Table 3 lists carbonic anhydrase inhibitors, drugs that reduce metformin clearance, alcohol, insulin or insulin secretagogues, and drugs that raise blood glucose; semaglutide is not in that table [2].

Does Wegovy change how metformin is absorbed?

Wegovy delays gastric emptying, and the label says this has the potential to affect absorption of oral medicines [1]. The label also says that in clinical pharmacology trials with semaglutide 1 mg once-weekly injection, semaglutide did not affect the absorption of orally administered medicines [1]. In semaglutide interaction studies, no clinically significant effect was seen on metformin, lisinopril, warfarin, digoxin, ethinyl estradiol, levonorgestrel, furosemide or rosuvastatin [1]. One exception: in a study with the semaglutide tablet, levothyroxine exposure (AUC) rose 33% [1]. The label advises increased clinical or laboratory monitoring with oral medicines that have a narrow therapeutic index or require clinical monitoring [1].

Is hypoglycemia a concern with Wegovy plus metformin?

Wegovy lowers blood glucose and can cause hypoglycemia [1]. The risk is increased when Wegovy is used with insulin or an insulin secretagogue such as a sulfonylurea; the label says to consider reducing the insulin or secretagogue dose when starting Wegovy [1]. The metformin label names the same two classes as the combinations that raise hypoglycemia risk and says lower doses of those may be needed [2]. In a Wegovy weight trial in adults with type 2 diabetes and BMI 27 or higher, glucose below 54 mg/dL occurred in 6.2% on Wegovy 2.4 mg vs 2.5% on placebo, and risk was higher with a sulfonylurea [1].

What GI side effects do the labels report?

In pooled trials of Wegovy 2.4 mg injection, nausea occurred in 44% vs 16% on placebo, diarrhea in 30% vs 16%, vomiting in 24% vs 6%, constipation in 24% vs 11%, and abdominal pain in 20% vs 10%; any GI reaction occurred in 73% vs 47% [1]. In a US trial of immediate-release metformin up to 2,550 mg/day, diarrhea occurred in 53% vs 12% on placebo, nausea or vomiting in 26% vs 8%, flatulence in 12% vs 6%, indigestion in 7% vs 4%, and abdominal discomfort in 6% vs 5%; diarrhea led to discontinuation in 6% [2]. Both labels describe GI symptoms as common, and neither gives a combined rate for the two drugs taken together.

What kidney checks does metformin require?

Metformin is cleared by the kidneys, and the label says to obtain eGFR before starting and at least yearly [2]. Metformin is contraindicated at eGFR below 30 mL/min/1.73 m2; initiation is not recommended at eGFR 30 to 45; if eGFR later falls below 45, the label says to assess the benefit and risk of continuing, and to discontinue if eGFR falls below 30 [2]. The boxed warning is lactic acidosis, with risk factors including renal impairment, age 65 or older, contrast studies, surgery and other procedures, hypoxic states such as acute congestive heart failure, excessive alcohol intake, and hepatic impairment [2].

Wegovy's label warns about acute kidney injury due to volume depletion and says to monitor renal function in patients reporting adverse reactions that could lead to volume depletion [1]. Its pharmacokinetic data found no clinically significant differences in semaglutide exposure across eGFR 30 to under 90 [1].

What about iodinated contrast?

The metformin label says to stop metformin at the time of or before an iodinated contrast imaging procedure in patients with eGFR 30 to 60, a history of hepatic impairment, alcoholism or heart failure, or when intra-arterial iodinated contrast is used; the label says to re-evaluate eGFR 48 hours afterward and restart only if renal function is stable [2].

Does metformin affect vitamin B12?

The metformin label reports a decrease to subnormal B12 levels in approximately 7% of patients in 29-week trials and says to measure hematologic parameters annually and B12 at 2 to 3 year intervals [2]. In the Diabetes Prevention Program Outcomes Study, low B12 (203 pg/mL or less) occurred in 4.3% on metformin vs 2.3% on placebo at 5 years, and 7.4% vs 5.4% at 13 years (not significant); low plus borderline-low B12 (298 pg/mL or less) occurred in 19.1% vs 9.5% at 5 years and 20.3% vs 15.6% at 13 years [3]. The odds of B12 deficiency rose 13% per year of metformin use (OR 1.13, 95% CI 1.06 to 1.20) [3].